Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Tumor fraction change is predictive of outcomes in patients undergoing immune checkpoint inhibitors.
• Baseline detection of tumor fraction appears to have prognostic significance, guiding future interventions.
• Assessment of tumor fraction change in a real-world setting can offer insights into clinical benefits of treatment.
• Findings may enable better patient selection for immune checkpoint inhibitor therapy in oncological practice.

Abstract